Generic Release Of Vimpat Is Now Available

Released: 03/30/2022  

The generic formulation of Vimpat, Lacosamide, has been released. Lacosamide is indicated as monotherapy or adjunctive therapy in certain patients with partial onset seizures and as adjunctive therapy in certain patients with primary generalized tonic-clonic seizures. 

The generic formulation of Lacosamide is currently manufactured by Camber Pharmaceuticals, Glenmark Pharma INC USA and Vista Pharm INC. Lacosamide is available as 50mg, 100mg, 150mg, 200mg tablets and 10mg/ml oral solution. 

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your workers’ compensation pharmacy needs, please contact us at 800-553-1783 or at